clinical experience with therapeutic dose of low-molecular-weight heparin. ¬© 2020, EDIMES Edizioni Medico Scientifiche. All rights reserved.A 71-year old gentleman With history of arterial hypertension treated With valsartan presented on Was hospitalized at the Infectious Diseases Unit, University of Bologna (Italy) for severe acute respiratory syndromecoronavirus-2 (SARS-CoV-2) and received treatment With hydroxychloroquine 200mg bid (400 mg bid the first day), azithromycin 400 mg qd, thrombotic prophylaxis With enoxaparin 4000 UI qd and Venturi mask oxygen delivering FiO2 of 31%. The case highlights the high frequency of coagulopathy in patients With moderate to severe cases of SARSCoV-2 associated disease (COVID-19). After one Week the patient significantly improved and the daily dose of enoxaparin Was reduced and definitively discontinued four days later. The case highlights the high frequency of coagulopathy in patients With moderate to severe cases of SARSCoV-2 associated disease (COVID-19). Considering the available information We believe that LMwH may represent a promising treatment for COVID-19 but further Well-designed trials are needed to address these points.